CTLA4 and exanthem: They summarized the advantages and limitations of immune checkpoint inhibitors in tumor therapy, as well as immunotherapy-related adverse event and management. Patients treated with anti-CTLA-4 had a higher incidence of side effects than those treated with anti-PD-1. Certain treatment-related autoimmune reactions such as rash and vitiligo were associated with better outcomes.